Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023
July 07 2023 - 8:00AM
Esperion (NASDAQ: ESPR) today announced the presentation of a key
abstract at the 2023 ASPC Congress on CVD Prevention taking place
on July 21-23, 2023, in Arlington, TX.
Session Type: |
|
Poster Session |
|
|
|
Date/Time: |
|
July 20, 2023: 2:00 – 8:00 p.m. ETJuly 21, 2023: 7:00 – 9:30 a.m.
ET |
|
|
|
Poster #: |
|
136 |
|
|
|
Abstract Title: |
|
Background ezetimibe use among participants in the CLEAR Outcomes
trial |
|
|
|
Location: |
|
Poster Hall Area, Arlington Ballroom |
|
|
|
AND |
|
|
|
|
|
Session Type: |
|
Poster Session - Author Q&A |
|
|
|
Date/Time: |
|
July 21, 2023: 11:35 a.m. – 12:00 p.m. ET, 2:55 – 3:10 p.m. ET,
5:40 – 6:00 p.m. ETJuly 22, 2023: 2:35 – 2:50 p.m. ETJuly 23, 2023:
10:40 – 10:55 a.m. ET |
|
|
|
Presentation Title: |
|
Background ezetimibe use among participants in the CLEAR Outcomes
trial |
|
|
|
Location: |
|
Poster Hall Area, Arlington Ballroom |
|
|
|
Presenter: |
|
Luke Laffin, MD, Co-Director, Center for Blood Pressure Disorders
at Cleveland Clinic |
|
|
|
Esperion TherapeuticsAt Esperion, we discover,
develop, and commercialize innovative medicines to help improve
outcomes for patients with or at risk for cardiovascular and
cardiometabolic diseases. The status quo is not meeting the health
needs of millions of people with high cholesterol – that is why our
team of passionate industry leaders is breaking through the
barriers that prevent patients from reaching their goals. Providers
are moving toward reducing LDL-cholesterol levels as low as
possible, as soon as possible; we provide the next steps to help
get patients there. Because when it comes to high cholesterol,
getting to goal is not optional. It is our life’s work. For more
information, visit esperion.com and esperionscience.com and follow
us on Twitter at twitter.com/EsperionInc.
CLEAR Cardiovascular Outcomes TrialCLEAR
Outcomes is part of the CLEAR clinical research program for
NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and
ezetimibe) Tablet. The CLEAR Program seeks to generate important
clinical evidence on the safety and efficacy of bempedoic acid, a
first in a class ATP citrate lyase inhibitor contained in NEXLETOL
and NEXLIZET and its potential role in addressing additional
critical unmet medical needs. More than 60,000 people will have
participated in the program by the time of its completion. The
CLEAR Program includes 5 label-enabling Phase III studies as well
as other key Phase IV studies with the potential to reach more than
70 million people with or at risk for CVD based on elevated
LDL-C.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements regarding regulatory submissions and potential
approvals, marketing strategy and commercialization plans, current
and planned operational expenses, future operations, commercial
products, clinical development, including the timing, designs and
plans for the CLEAR Outcomes study and its results, plans for
potential future product candidates, financial condition and
outlook, including expected cash runway, and other statements
containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,” and
similar expressions. Any express or implied statements contained in
this press release that are not statements of historical fact may
be deemed to be forward-looking statements. Forward-looking
statements involve risks and uncertainties that could cause
Esperion’s actual results to differ significantly from those
projected, including, without limitation, the impact of the ongoing
COVID-19 pandemic on our business, revenues, results of operations
and financial condition, the net sales, profitability, and growth
of Esperion’s commercial products, clinical activities and results,
supply chain, commercial development and launch plans, the outcomes
of legal proceedings, and the risks detailed in Esperion’s filings
with the Securities and Exchange Commission. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Esperion disclaims any obligation or undertaking
to update or revise any forward-looking statements contained in
this press release, other than to the extent required by law.
Esperion Contact Information:Investors: Alexis
Callahaninvestorrelations@esperion.com (406) 539-1762
Media: Tiffany Aldrich corporateteam@esperion.com (616)
443-8438
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From May 2024 to Jun 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2023 to Jun 2024